Heart failure & cardiomyopathies
Baroreflex Activation Therapy in Advanced Heart Failure Therapy: Insights from a Real-World Scenario
Authors' conclusion
Although BAT has generated considerable interest, acceptance appears to be ambivalent. BAT improves outcome with regard to LVEF, NYHA class, QoL, NT-proBNP levels, and HF hospitalization rates. BAT + ARNI resulted in more pronounced effects than ARNI alone.
Study context
- Population
- Patients with advanced HFrEF (71 ± 3 years, 20% female)10 opted for baroreflex activation therapy (BAT) implantation
- Participants
- 40 patients
- Exposure
- BAT vs guideline-directed medical therapy (GDMT) alone
- Outcome
- Improvement in QoL, NYHA class, LVEF, HF hospitalization, NT-proBNP levels and 6MHWD
- Follow-up
- At 3, 6 and 12 months
Main finding
As reported in the abstract
| Outcome | BAT | BAT + ARNI | Control | P value |
|---|---|---|---|---|
| LVEF | +10%, P = 0.005* | +9%, P = 0.049* | — not stated in the abstract | |
| NYHA class | −88%, P = 0.014* | −90%, P = 0.037* | — not stated in the abstract | |
| QoL | +21%, P = 0.020* | +22%, P = 0.012* | — not stated in the abstract | |
| NT-proBNP | −24%, P = 0.297 | −37%, P = 0.297 | — not stated in the abstract | |
| HF hospitalization | 50% | — not stated in the abstract | 83% | P = 0.020* |
— not stated in the abstract
Observational data: associations, not effects.
Further findings
Acceptance of BAT (questionnaire)
- Showed interest in BAT
- 29 (73%)
- Opted for implantation
- 10 (25%)
Original publication
Baroreflex Activation Therapy in Advanced Heart Failure Therapy: Insights from a Real-World Scenario. ESC Heart Fail. Published 8 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →